Degradation prediction, drug

Pharmaceutical Stress Testing Predicting Drug Degradation, edited by Steven W. Baertschi... 

At least two systems can be cited as catalysts of peroxide oxidation the first are the iron (III) porphyrins (44) and the second are the Gif reagents (45,46), based on iron salt catalysis in a pyridine/acetic acid solvent with peroxide reagents and other oxidants. The author s opinion is that more than systems for stress testing these are tools useful for the synthesis of impurities, especially epoxides. From another point of view, they are often considered as potential biomimetic systems, predicting drug metabolism. Metabolites are sometimes also degradation impurities, but this is not a general rule, because enzymes and free radicals have different reactivity an example is the metabolic synthesis of arene oxides that never can be obtained by radical oxidation. 

Fasani, E., and Albini, A. (2005), Photostability stress testing, in Baertschi, S. W., Ed., Pharmaceutical Stress Testing Predicting Drug Degradation, Taylor and Francis, Boca... 

E. Fasani and A. Albini, PhotostabiUty stress testing. Chapter 10 in Pharmaceutical Stress Testing Predicting Drug Degradation, edited by S. W. Baertschi, 1 edition, Vol. 153, Dmgs and the Pharmacentical Sciences Series (Taylor and Francis), 2005. 

Pharmaceutical Stress Testing Predicting Drug Degradation... 

Baertschi SW (2007) Pharmaceutical stress testing predicting drug degradation. In Baertschi SW (ed), Informa Healthcare, USA, Inc., vol 153, pp. 13-49. 

Baertschi SW (2005) Pharmaceutical stress testing predicting drug degradation. Taylor Francis, Boca Raton. 

S. M. Reutzel-Edens and G. A. Stephenson, in Pharmaceutical Stress Testing, Predicting Drug Degradation, Second Edition, ed. S. W. Baertschi, K. Alsante and R. A. Reed, Informa Healthcare USA, Inc., New York, 2011, pp. 254 285. 

Baertschi, S. W. and Reynolds, D. W. Chapter 1 Stress Testing Introduction. In Pharmaceutical Stress Testing Predicting Drug Degradation, (S. W. Baertschi, ed.), Taylor Francis Group, Boca Raton, FL, pp. 1-12, 2005. 

It is convenient to start the discussion of degradation models with amorphous polymers. A typical application of amorphous polymers in medical devices is the drug-carrying layer of coronary stents. Calculating the degradation rate of the polymer is the first step to predict drug-release profile from a stent. Furthermore, all semi-crystalline polymers contain an amorphous phase. It is therefore logical to focus attention on amorphous polymers first. Semi-crystalline polymers are considered in Chapter 4. 

---